Tumor-specific gene therapy for uterine cervical cancer using MN/CA9-directed replication-competent adenovirus

Cancer Gene Therapy

Volumn 11, Issue 8, 2004, Pages 532-538

  Lim, Ho Yeong ^a   Ahn, Miwon ^a   Chung, Hyun Cheol ^b   Gardner, Thomas A ^c   Kao, Chinghai ^c   Lee, Sang Jin ^c   Kim, Se Joong ^a  

^a Ajou University School of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenovirus; Cervix neoplasms; MN CA9; Virus replication

Indexed keywords

ADENOVIRUS VECTOR; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE IX; E1A PROTEIN; MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL GROWTH; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; FEMALE; GENE CONSTRUCT; GENE EXPRESSION; GENE IDENTIFICATION; GENE TARGETING; GENE THERAPY; GROWTH INHIBITION; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; UTERINE CERVIX CANCER; VIRUS RECOMBINANT; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ANIMALS; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; FEMALE; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HELA CELLS; HUMANS; MICE; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; UTERINE CERVICAL NEOPLASMS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; ANIMALIA; MUS MUSCULUS;

EID: 4043118903     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700732     Document Type: Article

References (36)

1. Greenlee RT, Murray T, Bolden S, et al. Cancer statistics, 2000. CA Cancer J Clin. 2000;50:7-33.
2. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer. 1999;80:827-841.
3. Orr Jr JW, Shingleton HM, Hatch KD, et al. Correlation of perioperative morbidity and conization to radical hysterectomy interval. Obstet Gynecol. 1982;59:726-731.
4. Forney JP. The effect of radical hysterectomy on bladder physiology. Am J Obstet Gynecol. 1980;138:374-382.
5. Ralph G, Tamussino K, Lichtenegger W. Urological complications after radical hysterectomy with or without radiotherapy for cervical cancer. Arch Gynecol Obstet. 1990;248:61-65.
6. Nguyen HN, Nordqvist SR. Chemotherapy of advanced and recurrent cervical carcinoma. Semin Surg Oncol. 1999;16:247-250.
7. Omura GA. Chemotherapy for stage IVB or recurrent cancer of the uterine cervix. J Natl Cancer Inst Monogr. 1996;21:123-126.
8. Der CJ, Stanbridge EJ. A tumor-specific membrane phosphoprotein marker in human cell hybrids. Cell. 1981;26:429-438.
9. Opavsky R, Pastorekova S, Zelnik V, et al. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics. 1996;33:480-487.
10. Pastorek J, Pastorekova S, Callebaut I, et al. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene. 1994;9:2877-2888.
11. Liao SY, Brewer C, Zavada J, et al. Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas. Am J Pathol. 1994;145:598-609.
12. Liao SY, Stanbridge EJ. Expression of MN/CA9 protein in Papanicolaou smears containing atypical glandular cells of undetermined significance is a diagnostic biomarker of cervical dysplasia and neoplasia. Cancer. 2000;88:1108-1121.
13. McKiernan JM, Buttyan R, Bander NH, et al. Expression of the tumor-associated gene MN: a potential biomarker for human renal cell carcinoma. Cancer Res. 1997;57:2362-2365.
14. Uemura H, Nakagawa Y, Yoshida K, et al. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br J Cancer. 1999;81:741-746.
15. Turner JR, Odze RD, Crum CP, et al, MN antigen expression in normal, preneoplastic, and neoplastic esophagus: a clinicopathological study of a new cancer-associated biomarker. Hum Pathol. 1997;28:740-744.
16. Vermylen P, Roufosse C, Burny A, et al. Carbonic anhydrase IX antigen differentiates between preneoplastic malignant lesions in non-small cell lung carcinoma. Eur Respir J. 1999;14:806-811.
17. Saarnio J, Parkkila S, Parkkila AK, et al. Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. Am J Pathol. 1998;153:279-285,
18. Bartosova M, Parkkila S, Pohlodek K, et al. Expression of carbonic anhydrase IX in breast is associated with malignant tissues and is related to overexpression of c-erbB2. J Pathol. 2002;197:314-321.
19. Vile RG, Russell SJ, Lemoine NR. Cancer gene therapy: hard lessons and new courses. Gene Ther. 2000;7:2-8.
20. Zhang WW. Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Ther. 1999;6:113-138.
21. Zhang L, Akbulut H, Tang Y, et al. Adenoviral vectors with E1A regulated by tumor-specific promoters are selectively cytolytic for breast cancer and melanoma. Mol Ther. 2002;6:386-393.
22. Kirn D. Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer. Oncogene. 2000;19:6660-6669.
23. Ebert T, Bander NH, Finstad CL, et al. Establishment and characterization of human renal cancer and normal kidney cell lines. Cancer Res. 1990;50:5531-5536.
24. Fallaux FJ, Kranenburg O, Cramer SJ, et al. Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum Gene Ther. 1996;7:215-222.
25. Fallaux FJ, Bout A, van der Velde I, et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther. 1998;9:1909-1917.
26. Bett AJ, Haddara W, Prevec L, et al. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA. 1994;91:8802-8806.
27. Zhang WW, Fang X, Branch CD, et al. Generation and identification of recombinant adenovirus by liposome-mediated transfection and PCR analysis. Biotechniques. 1993;15:868-872.
28. Ko SC, Cheon J, Kao C, et al. Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models. Cancer Res. 1996;56:4614-4619.
29. Rodriguez R, Schuur ER, Lim HY, et al. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 1997;57:2559-2563.
30. Hallenbeck PL, Chang YN, Hay C, et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene Ther. 1999;10:1721-1733.
31. Loncaster JA, Harris AL, Davidson SE, et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res. 2001;61:6394-6399.
32. Stanbridge EJ, Der CJ, Doersen CJ, et al. Human cell hybrids: analysis of transformation and tumorigenicity. Science. 1982;215:252-259.
33. Pastorekova S, Zavadova Z, Kostal M, et al. A novel quasiviral agent, MaTu, is a two-component system. Virology. 1992;187:620-626.
34. Zavada J, Zavadova Z, Pastorekova S, et al. Expression of MaTu-MN protein in human tumor cultures and in clinical specimens. Int J Cancer. 1993;54:268-274.
35. Graham FL, Smiley J, Russell WC, et al. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol. 1977;36:59-72.
36. Shirakawa T, Gardner TA, Ko SC, et al. Cytotoxicity of adenoviral-mediated cytosine deaminase plus 5-fluorocytosine gene therapy is superior to thymidine kinase plus acyclovir in a human renal cell carcinoma model. J Urol. 1999;162:949-954.